Omada Health raises $23 million in Series B funding led by Andreessen Horowitz
Omada Health has raised $23 million in Series B funding led by Andreessen Horowitz with participation from Kaiser Permanente Ventures, U.S. Venture Partners, and The Vertical Group. Andreessen Horowitz general partner Balaji Srinivasan will be joining Omada’s board of directors.
What does Omada do? The company creates and delivers health programs to achieve clinical outcomes and help participants reverse chronic diseases or its complications, which are costly to employers and the patient. The Omada team includes a group of clinicians and designers that worked at Google, Harvard University, Stanford University, Amazon.com, and IDEO that are passionate about creating technology to prevent diseases.
“We’re caught in an unacceptable paradox: despite staggering technological advances in nearly every aspect of our lives, for the first time in history we find that preventable, chronic disease now kills more people than infectious disease,” stated Sean Duffy, CEO and co-founder of Omada Health. “Omada’s mission is to inspire people to alter the habits that place them at risk for serious but preventable conditions. This vote of confidence from Andreessen Horowitz, combined with the work we’re already doing for major organizations like Blue Cross Blue Shield Louisiana and Stanford Hospital, reinforces our belief that consumers are ready for health programs that are rooted in science and tangible outcomes, yet are designed and delivered digitally as natural extensions of how we live today.”